What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cardiology
Eugene P. McFadden mainly investigates Internal medicine, Cardiology, Stent, Surgery and Myocardial infarction.
His work on Coronary artery disease, Clopidogrel, ST segment and Prospective cohort study as part of general Internal medicine research is frequently linked to Risk assessment, thereby connecting diverse disciplines of science.
His Cardiology study incorporates themes from Thrombosis and Radiology.
His Stent research integrates issues from Percutaneous coronary intervention, TIMI and Sirolimus.
In the field of Surgery, his study on Clinical endpoint, Bare-metal stent and Randomized controlled trial overlaps with subjects such as Antibacterial agent.
His Myocardial infarction research includes themes of Discontinuation, Randomization and Hazard ratio.
His most cited work include:
- Clinical End Points in Coronary Stent Trials A Case for Standardized Definitions (4102 citations)
- Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. (1287 citations)
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). (1195 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Cardiology, Surgery, Myocardial infarction and Angioplasty.
His work in the fields of Internal medicine, such as Coronary artery disease, Percutaneous coronary intervention, Angina and Artery, intersects with other areas such as In patient.
His studies in Cardiology integrate themes in fields like Restenosis and Angiography, Radiology.
His study in Stent, Drug-eluting stent, Percutaneous and Thrombosis is carried out as part of his Surgery studies.
In general Stent study, his work on Coronary stent often relates to the realm of Antibacterial agent, thereby connecting several areas of interest.
Eugene P. McFadden works mostly in the field of Myocardial infarction, limiting it down to topics relating to Clinical endpoint and, in certain cases, Stroke.
He most often published in these fields:
- Internal medicine (65.67%)
- Cardiology (60.09%)
- Surgery (36.91%)
What were the highlights of his more recent work (between 2010-2021)?
- Internal medicine (65.67%)
- Cardiology (60.09%)
- Percutaneous coronary intervention (15.88%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Cardiology, Percutaneous coronary intervention, Myocardial infarction and Surgery are his primary areas of study.
His Coronary artery disease, Coronary atherosclerosis, Core laboratory and QT interval study in the realm of Internal medicine connects with subjects such as In patient.
Eugene P. McFadden has researched Cardiology in several fields, including Biomarker and Percutaneous.
His Percutaneous coronary intervention research is multidisciplinary, incorporating elements of Conventional PCI, Renal function and Confidence interval.
His research investigates the connection with Myocardial infarction and areas like Clinical endpoint which intersect with concerns in Stroke and Prospective cohort study.
Stent is the focus of his Surgery research.
Between 2010 and 2021, his most popular works were:
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). (1195 citations)
- Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial (259 citations)
- 2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial) (177 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Myocardial infarction
Eugene P. McFadden mostly deals with Clinical trial, Surgery, Myocardial infarction, Internal medicine and Randomized controlled trial.
The concepts of his Clinical trial study are interwoven with issues in Outcome assessment, Surrogate endpoint, Medical education and Intensive care medicine.
Eugene P. McFadden is interested in Stent, which is a field of Surgery.
He works in the field of Myocardial infarction, focusing on Percutaneous coronary intervention in particular.
His study looks at the relationship between Internal medicine and fields such as Cardiology, as well as how they intersect with chemical problems.
The various areas that Eugene P. McFadden examines in his Randomized controlled trial study include Sirolimus, Revascularization, Electrocardiography, Prospective cohort study and Subgroup analysis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
